More importantly, we proved that ANKRD12 expression was significantly associated with overall survival of CRC patients. In support of this, Kaplan–Meier analysis of overall survival showed that patients whose tumors had lower ANKRD12 expression tend to have a significantly worse overall survival, indicating that low ANKRD12 level is a marker of poor prognosis for CRC patients. Moreover, Cox proportional hazards model showed that low ANKRD12 expression

was an independent prognostic predictor for CRC patients. Therefore, ANKRD12 could constitute a molecular prognostic RGFP966 solubility dmso marker for CRC patients, identifying who are more likely to have higher risk of death and need receive a more aggressive treatment. The precise molecular mechanisms behind the altered expression of ANKRD12 in colorectal cancer are unclear. To our knowledge, this is the first report to describe the significance of ANKRD12 to clinical stage, lymph node and liver metastases, and prognosis of CRC patients. ANKRD12 binds to alteration/deficiency in activation 3(ADA3)

through its C-terminal domain and inhibits ADA3-mediated transcriptional co-activation on NRs [7]. ADA3 is a component of the human P/CAF acetyltransferase complex which is thought to link co-activators to histone acetylation and basal transcription machinery [14]. Gene expression regulated by NRs, therefore ANKRD12 may regulate some important gene expression by inhibiting ADA3-mediated transcriptional co-activation on NRs. Recently, ADA3 is also identified Anidulafungin (LY303366) as APR-246 supplier a p53-binding protein [15–17], as well as causing p53 acetylation [18]. In mammalian cells, overexpression of ADA3 increased p53 levels [16]. P53 was identified as a tumor suppressor protein and is the most commonly mutated gene in human cancers [19–21]. However, ANKRD12 has little or no effect to promote p53 activation [7]. So we speculated that the effects of ANKRD12 in tumor development or progression might, through binding to ADA3 co-activators, increasing p53 levels and inhibit tumor development or progression. Additional Selleckchem Alpelisib studies

to investigate the real molecular mechanisms of altered expression of ANKRD12 in the development or progression of CRC are essential. Conclusions In conclusion, we found that ANKRD12 mRNA were downregulated in CRC tumor tissues and low ANKRD12 mRNA expression correlated with poor overall survival and liver metastasis of CRC patients. These findings suggest that ANKRD12 is a cancer-related gene associated with liver metastasis and a survival predictor of CRC patients. Consent Written informed consent was obtained from the patient for publication of this report and any accompanying images. Acknowledgements We thank Jun Ye, Hai Liu, Zhixuan Fu and Zhigang Chen for their technical assistance and the entire laboratory for fruitful discussions.